In addition, in the experimental setting of animal models of inflammatory bowel disease, SIRT1 can also reduce intestinal inflammatory responses and tissue damage by inhibiting ER stress response and the activity of the NF-κB pathway in the intestinal epithelial and immune cells, which maintain the intestinal barrier function (Caruso et al., 2014). Here, NFKB1 is linked to inflammatory bowel disease.